---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-115874"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-10-14T21:11:48+00:00"
generated_at: "2026-10-14T21:12:05.752767+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Rezolute completes Phase 3 upLIFT enrollment; topline ersodetug data expected mid-December 2026

## Summary
- Phase 3 upLIFT fully enrolled 16 participants with insulinoma or non-islet cell tumors causing uncontrolled hypoglycemia; topline results expected mid-December 2026.
- Primary endpoint: at least 50% reduction from baseline in IV glucose infusion rate; responder rate must be at least 56% (95% CI 30-80%) for significance.
- 7 of the first 8 participants met the responder criterion and all 7 fully discontinued IV glucose; the eighth entered hospice and died of cancer progression, counted as a non-responder.
- Ersodetug given at 9 mg/kg weekly for 8 weeks as add-on to standard of care; well-tolerated with no drug-related safety findings reported to date.
- Company continues expanded access for compassionate use in tumor HI and sees potential to advance both indications in 2027 if outcomes are favorable.

## SEC filing metadata
- accession: 0001104659-26-115874
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-10-14T21:11:48+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926115874/0001104659-26-115874-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926115874/tm2627620d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-115874
- JSON: https://secwatch.observer/filing/0001104659-26-115874.json
- Plain text: https://secwatch.observer/filing/0001104659-26-115874.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.